Related Experiment Video
Updated: May 3, 2026
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
Published on: March 13, 2018
Leveraging real-world data to advance biomarker discovery and precision oncology
1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; BCMB Allied Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA.
Abstract:
Precision oncology is predicated on the availability of robust biomarkers deployed at scale at the point of care. Although simple in conception, precision oncology often fails in practice because of the limitations of current diagnostic platforms, the emergence of drug resistance, and an incomplete understanding of cancer pathogenesis and the host immune response. Here, we discuss using real-world data, including exceptional responder analyses, to identify biomarkers of therapy response and strategies for overcoming barriers to the broader adoption of precision oncology paradigms.
Insights
Precision oncology relies on biomarkers, but faces challenges like drug resistance. Real-world data and exceptional responder analyses can identify new biomarkers and improve cancer treatment strategies.
Area of Science:
- Oncology
- Biomarker Discovery
- Translational Medicine
Background:
- Precision oncology aims to tailor cancer treatments using biomarkers.
- Current diagnostic platforms and understanding of cancer biology limit its widespread application.
- Drug resistance and host immune responses present significant hurdles.
Purpose of the Study:
- To discuss the challenges hindering precision oncology.
- To explore the use of real-world data for biomarker identification.
- To propose strategies for overcoming adoption barriers in precision oncology.
Main Methods:
- Review of current limitations in precision oncology.
- Analysis of real-world data, including exceptional responders.
- Identification of biomarkers predictive of therapy response.
Main Results:
- Real-world data, particularly exceptional responder analyses, can reveal novel biomarkers.
- Understanding drug resistance and immune response is crucial for treatment efficacy.
- Strategies are needed to integrate biomarker discovery with clinical practice.
Conclusions:
- Overcoming limitations requires innovative approaches to biomarker discovery and validation.
- Real-world data offers a powerful resource for advancing precision oncology.
- Broader adoption necessitates addressing diagnostic, resistance, and biological understanding challenges.
More Related Videos
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 20, 2019
07:34Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
